Oral GLP-1 Weight-Loss Tablets

Oral GLP-1 Weight-Loss Tablets: How Do They Compare With Weight-Loss Injections?

Weight-management treatment is entering a new phase. Until recently, some of the most effective newer medicines for weight management were associated primarily with once-weekly injections. In 2026, however, the UK authorised new oral GLP-1 treatments for weight management, giving suitable adults another potential treatment option.

So, how do the new tablets work, how effective are they, and how do they compare with injectable treatments?

 

What are GLP-1 medicines?

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone released after eating.

Medicines that act on the GLP-1 pathway can help regulate appetite by:

• Increasing feelings of fullness
• Reducing hunger
• Reducing food cravings
• Slowing gastric emptying
• Helping regulate blood glucose

These effects can reduce overall calorie intake and support weight loss when treatment is combined with appropriate dietary changes and physical activity.

Until recently, injectable treatments have dominated this area of weight management. The development of effective oral formulations therefore represents an important change.

 

What oral GLP-1 treatments are now available?

Two important oral treatments have recently emerged in the UK: oral semaglutide and orforglipron.

Wegovy (Oral semaglutide)

In June 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) authorised a tablet formulation of semaglutide for weight management in the UK.

It became the first GLP-1 receptor agonist tablet authorised in the UK specifically for weight loss and weight management.

Oral semaglutide contains the same active ingredient used in injectable semaglutide treatment, but it is taken once daily rather than once weekly.

Treatment starts at 1.5 mg once daily and is gradually increased through 4 mg and 9 mg to a maintenance dose of 25 mg, where appropriate.

There is one important consideration: oral semaglutide needs to be taken under specific conditions. The tablet should be taken after fasting for at least eight hours, with a small amount of water, and patients should then wait at least 30 minutes before eating, drinking or taking other oral medicines.

This is necessary because food and drink can significantly affect the absorption of oral semaglutide.

 

Foundayo (Orforglipron): a different type of oral GLP-1

In August 2026, the MHRA authorised Orforglipron for weight management and type 2 diabetes, making the UK the first country in Europe to authorise this treatment.

Orforglipron is particularly interesting because, unlike semaglutide, it is a small-molecule GLP-1 receptor agonist rather than a peptide-based medicine.

It is also taken once daily.

One potential practical advantage is that orforglipron can be taken at any time of day without restrictions relating to food or water.

Treatment is introduced gradually, beginning at a low dose and increasing over several months according to the prescribed treatment plan.

 

How effective are oral GLP-1 medicines?

Clinical trials suggest that oral GLP-1 treatment can produce substantial weight reduction, although results vary between medicines, doses and individual patients.

In the OASIS 4 clinical trial, adults with overweight or obesity receiving oral semaglutide 25 mg achieved substantial reductions in body weight over approximately 16 months.

Orforglipron has also demonstrated clinically meaningful weight reduction. In the ATTAIN-1 study, adults without diabetes receiving the highest studied dose achieved an average reduction in body weight of approximately 12.4% after 72 weeks, compared with approximately 0.9% with placebo.

Importantly, clinical-trial averages should not be interpreted as predictions of how much weight an individual person will lose.

 

How do the tablets compare with injections?

This is likely to be one of the most important questions for patients.

Feature	Wegovy Tablets	Foundayo	Wegovy Injection	Mounjaro
Administration	Tablet	Tablet	Injection	Injection
Frequency	Once daily	Once daily	Once weekly	Once weekly
GLP-1 activity	Yes	Yes	Yes	Yes
Additional GIP activity	No	No	No	Yes
Needles required	No	No	Yes	Yes
Food restrictions when taking	Yes	No	Not applicable	Not applicable
Weight-loss potential	High	High	High	Very high in clinical trials
Dose escalation required	Yes	Yes	Yes	Yes

 

The most important point is that oral treatment is not automatically better or worse than injectable treatment.

The appropriate medicine depends on the individual patient.

 

What do the clinical trials tell us about weight loss?

Comparing percentages between different clinical trials needs considerable caution because the studies involved different participants, treatment durations, doses and methodologies.

However, the results provide a useful indication of the potential effectiveness of the different approaches.

In the STEP 1 trial, once-weekly injectable semaglutide 2.4 mg produced an average body-weight reduction of approximately 14.9% after 68 weeks.

In the SURMOUNT-1 trial, once-weekly injectable tirzepatide produced average weight reductions of approximately 15.0%, 19.5% and 20.9% at 72 weeks for the 5 mg, 10 mg and 15 mg doses respectively.

Orforglipron 36 mg—the trial formulation corresponding to the highest authorised Foundayo dose—produced an average reduction of approximately 12.4% at 72 weeks in ATTAIN-1.

Oral semaglutide 25 mg has also demonstrated weight reduction in the mid-to-high teens in its pivotal clinical development programme.

These figures should not be regarded as a direct head-to-head ranking. With the exception of trials specifically designed to compare treatments, results from separate clinical trials cannot establish that one medicine will produce a particular amount more weight loss than another in an individual patient.

 

Why might someone prefer a tablet?

For some patients, the biggest advantage is obvious: no injections.

A tablet may be attractive to people who:

• Dislike needles
• Are uncomfortable administering injections themselves
• Travel frequently
• Prefer oral medicines
• Have difficulty storing or transporting injectable medication
• Simply find taking a tablet more acceptable

Greater choice may also make it easier to find a treatment that patients can follow consistently over the longer term.

 

Why might injections still be preferred?

Tablets are not necessarily more convenient for everyone.

A once-weekly injection means treatment only needs to be administered once every seven days, whereas oral GLP-1 treatments are taken every day.

Oral semaglutide (Wegovy) also requires careful timing around food, drinks and other medicines.

Furthermore, injectable tirzepatide (Mounjaro) targets both GIP and GLP-1 receptors and has produced particularly large reductions in body weight in clinical trials.

For some patients, therefore, an injectable treatment may remain the most appropriate option.

 

Are the side effects different?

Oral and injectable GLP-1 treatments share many of the same potential gastrointestinal side effects.

Common effects can include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Indigestion
• Abdominal discomfort

These effects are often most noticeable when treatment is started or when the dose is increased.

Gradual dose escalation is therefore an important part of treatment.

There are also less common but potentially significant risks and contraindications that need to be considered before treatment is prescribed. A healthcare professional should review the patient’s medical history, current medication and individual risk factors before GLP-1 treatment is started.

 

Can someone simply change from an injection to a tablet?

Patients should not switch between GLP-1 treatments without appropriate clinical guidance.

Different medicines have different dosing schedules, strengths and pharmacological properties, and milligram doses cannot simply be compared between products.

There are authorised transition arrangements in certain circumstances—for example, the MHRA states that patients privately treated with once-weekly semaglutide 2.4 mg may, where clinically appropriate, be transitioned directly to oral semaglutide 25 mg once daily.

Any change should nevertheless be made following an individual clinical assessment.

 

Which option is best?

There is no single GLP-1 treatment that will be best for everyone.

The choice between oral and injectable treatment can depend on:

• Medical history
• BMI and weight-related health conditions
• Previous weight-management treatments
• Other medication
• Expected benefits and potential risks
• Side-effect tolerance
• Ability to follow the dosing instructions
• Preference for daily tablets versus weekly injections

For one person, avoiding injections may be the priority. For another, once-weekly administration may be much more convenient than remembering a tablet every day.

The aim should therefore be to select the most appropriate treatment for the individual rather than simply choosing the newest medicine.

 

The future of weight-management treatment

The introduction of oral GLP-1 medicines represents an important development in obesity treatment.

Patients now have the prospect of highly effective medical weight-management treatments without necessarily needing injections, while further oral and injectable medicines targeting GLP-1 and related metabolic pathways continue to be developed.

More treatment options should ultimately allow healthcare professionals to individualise weight-management treatment more effectively.

However, GLP-1 medicines remain prescription-only treatments. They should only be supplied following an appropriate clinical assessment and obtained from a legitimate, regulated healthcare provider.

Medication is also only one part of effective long-term weight management. Nutrition, physical activity, behavioural change and appropriate clinical monitoring remain important alongside pharmacological treatment.

 

Important information

This article is provided for general educational purposes and should not be considered a substitute for individual medical advice. Weight-management medicines are prescription-only medicines and are not suitable for everyone. Eligibility, contraindications, interactions and ongoing monitoring should be assessed by an appropriately qualified healthcare professional.